Amyotrophic Lateral Sclerosis Pipeline, FDA Approvals, Clinical Trials Assessment, and Companies 2024

DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2024," report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in Amyotrophic Lateral Sclerosis (ALS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report
• DelveInsight's Amyotrophic Lateral Sclerosis Pipeline analysis depicts a robust space with 90+ active players working to develop 100+ pipeline treatment therapies.
• The leading companies working in the Amyotrophic Lateral Sclerosis Market include Molecular Partners, Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetics, MediciNova, Retrotope, Inc., Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics Inc., Apellis Pharmaceuticals Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics Inc., Cellenkos, ZZ Biotech LLC, QurAlis Corporation, Alector Inc., NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Eledon Pharmaceuticals, and others.
• Promising Amyotrophic Lateral Sclerosis Pipeline Therapies in the various stages of development include Reldesemtiv, Albutein 5%, Tofersen, FAB122, sNN0029, ABBV-CLS-7262, SPG302, Dazucorilant 300 mg, AP-101, ION363, and others.
• March 2024: Corcept Therapeutics announced a study of Phase 2 clinical trials for Dazucorilant 300 mg. The purpose of this study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).
• February 2024: Spinogenix announced a study of Phase 1 clinical trials for SPG302. The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants.
• December 2023: MaaT Pharma announced a study of Phase 1 clinical trials for MaaT033. The purpose of this pilot study is to assess the safety and tolerability of multiple doses of MaaT033 in ALS patients and to analyze the gut microbiota composition and evolution before considering a larger randomized controlled efficacy study.
• December 2023: QurAlis Corporation announced a study of Phase 1 clinical trials for QRL-201- Dose 8. The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS.

Request a sample and discover the recent advances in Amyotrophic Lateral Sclerosis Treatment Drugs @ Amyotrophic Lateral Sclerosis Pipeline Outlook Report- https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Amyotrophic Lateral Sclerosis pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Amyotrophic Lateral Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

Amyotrophic Lateral Sclerosis Overview
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a rare neurological disease that affects motor neurons-those nerve cells in the brain and spinal cord that control voluntary muscle movement. Voluntary muscles are those we choose to move to produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. ALS has no cure and there is no effective treatment to reverse its progression. ALS is a type of motor neuron disease.

Find out more about Amyotrophic Lateral Sclerosis Treatment Landscape @ Drugs for Amyotrophic Lateral Sclerosis Treatment- https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Amyotrophic Lateral Sclerosis Emerging Drugs Profile
• Tofersen: Biogen
• RNS60: Revalesio Corporation
• ANX005: Annexon

Amyotrophic Lateral Sclerosis Pipeline Therapeutics Assessment
There are approx. 90+ key companies which are developing the therapies for Amyotrophic Lateral Sclerosis. The Amyotrophic Lateral Sclerosis companies which have their Amyotrophic Lateral Sclerosis drug candidates in the most advanced stage, i.e. Preregistration include, Biogen.

DelveInsight's Amyotrophic Lateral Sclerosis pipeline report covers around 100+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Learn more about the emerging Amyotrophic Lateral Sclerosis Pipeline Therapies @ Amyotrophic Lateral Sclerosis Clinical Trials Assessment- https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Amyotrophic Lateral Sclerosis Pipeline Report
• Coverage- Global
• Amyotrophic Lateral Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Amyotrophic Lateral Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Amyotrophic Lateral Sclerosis Companies- Molecular Partners, Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetics, MediciNova, Retrotope, Inc., Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics Inc., Apellis Pharmaceuticals Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics Inc., Cellenkos, ZZ Biotech LLC, QurAlis Corporation, Alector Inc., NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Eledon Pharmaceuticals, and others.
• Amyotrophic Lateral Sclerosis Therapies- Reldesemtiv, Albutein 5%, Tofersen, FAB122, sNN0029, ABBV-CLS-7262, SPG302, Dazucorilant 300 mg, AP-101, ION363, and others.

Dive deep into rich insights for new drugs for Amyotrophic Lateral Sclerosis Treatment, Visit @ Amyotrophic Lateral Sclerosis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Amyotrophic Lateral Sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Amyotrophic Lateral Sclerosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Tofersen: Biogen
9. Late Stage Products (Phase III)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. RNS60: Revalesio Corporation
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug Name: Company Name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Amyotrophic Lateral Sclerosis Key Companies
23. Amyotrophic Lateral Sclerosis Key Products
24. Amyotrophic Lateral Sclerosis- Unmet Needs
25. Amyotrophic Lateral Sclerosis- Market Drivers and Barriers
26. Amyotrophic Lateral Sclerosis- Future Perspectives and Conclusion
27. Amyotrophic Lateral Sclerosis Analyst Views
28. Amyotrophic Lateral Sclerosis Key Companies
29. Appendix

For further information on the Amyotrophic Lateral Sclerosis Pipeline Therapeutics, reach out @ Amyotrophic Lateral Sclerosis Unmet Needs and Analyst Views- https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-
https://wanneroo-social.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-current-trends-and-future-prospects
https://visbn.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-corneal-healing-challenges
https://globalaffairs.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-in-treatment-and-growing-opportunities
https://snapped.mn.co/posts/navigating-the-persistent-epithelial-defects-market-current-trends-and-future-outlook
https://keywebco.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-unmet-needs-and-driving-innovation
https://machineintelligence.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-and-opportunities
https://healthcaremarketresearch.edublogs.org/2024/03/13/navigating-the-landscape-of-persistent-epithelial-defects-market/
https://lgbtq-youth-chat.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-innovations-and-challenges
https://sarabestexchange73158582.mn.co/posts/unveiling-the-persistent-epithelial-defects-market-a-comprehensive-outlook
https://network-1588972.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-and-opportunities
https://rdd-rapter-gameing.mn.co/posts/persistent-epithelial-defects-market-outlook-addressing-the-unmet-needs-in-ocular-surface-disorders
https://rdd-rapter-gameing.mn.co/posts/persistent-epithelial-defects-market-outlook-addressing-the-unmet-needs-in-ocular-surface-disorders
https://vibe-3-0.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-and-opportunities
https://brand-the-change.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-and-opportunities
https://goodnow.mn.co/posts/exploring-the-persistent-epithelial-defects-market-a-niche-addressing-corneal-healing-challenges
https://lgbtq-youth-chat.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-innovations-and-challenges-52580993
https://inspiremetoday.mn.co/posts/unraveling-the-persistent-epithelial-defects-market-a-comprehensive-perspective
https://shopsanity.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-innovations-and-challenges
https://plenty-of-heathens.mn.co/posts/navigating-the-persistent-epithelial-defects-market-innovations-and-challenges
https://akademe.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-challenges-and-driving-innovation
https://naijases.mn.co/posts/navigating-the-persistent-epithelial-defects-market-innovations-and-challenges
https://gtribe.mn.co/posts/navigating-the-landscape-of-the-persistent-epithelial-defects-market
https://communenour.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-a-challenging-ophthalmic-condition
https://synkretic.mn.co/posts/navigating-the-landscape-of-the-persistent-epithelial-defects-market
https://lxgonline.mn.co/posts/exploring-the-persistent-epithelial-defects-market-a-comprehensive-analysis
https://regenerative-future.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-an-unmet-need
https://gamebook.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-challenges-and-opportunities
https://yizhanverse.mn.co/posts/understanding-the-persistent-epithelial-defects-market-a-glimpse-into-emerging-opportunities
https://clinalleve.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market
https://homes-for-homeless-children.mn.co/posts/52583828
https://weholdspace.mn.co/posts/52584896
https://boringbusiness.mn.co/members/16644151
https://businessboostier.mn.co/posts/52585024
https://amy-anisas-community.mn.co/posts/52585098
https://naitirabotu.mn.co/members/21957308
https://tech4goodwales.mn.co/posts/exploring-the-genital-herpes-market-outlook-trends-treatments-and-future-prospects
https://worldletinews.mn.co/members/20156129
https://local-urban-eats.mn.co/posts/52585609
https://wwwpreparatorianis.mn.co/posts/52585907
https://shaunbook.mn.co/posts/genital-herpes-market-outlook-advancements-and-challenges-ahead
https://playhq.mn.co/posts/52587238
https://linkasia.mn.co/posts/52587360
https://indicate.mn.co/posts/52587525
https://naijases.mn.co/posts/navigating-the-genital-herpes-market-current-trends-and-future-outlook
https://aeros.mn.co/posts/52587883
https://itravel.mn.co/members/20248979
https://churecipe.mn.co/posts/52588055
https://www-network-aus-au.mn.co/posts/genital-herpes-market-outlook-trends-treatments-and-future-prospects
https://mossfon.mn.co/posts/52588854
https://together.mn.co/posts/52589078
https://bipolarjungle.mn.co/posts/52589178
https://create-lifestyle.mn.co/posts/52589248
https://gelardas.mn.co/members/20249381
https://bloby.mn.co/posts/52589494
https://cic-mun.mn.co/posts/52589598
https://evening-newss.mn.co/members/20271728
https://omind.mn.co/members/20271735
https://shop1606.mn.co/posts/52589778

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website- https://www.delveinsight.com/consulting/primary-research-services

This release was published on openPR.